Tobacco and E-cigarette use among cancer survivors in the United States

Autoři: Ramzi G. Salloum aff001;  Jinhai Huo aff001;  Ji-Hyun Lee aff002;  Juhan Lee aff003;  Jesse Dallery aff004;  Thomas George aff001;  Graham Warren aff006
Působiště autorů: Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, United States of America aff001;  Division of Quantitative Sciences, University of Florida Health Cancer Center, Department of Biostatistics, University of Florida, Gainesville, Florida, United States of America aff002;  Department of Health Education and Behavior, University of Florida, Gainesville, Florida, United States of America aff003;  Department of Psychology, University of Florida, Gainesville, Florida, United States of America aff004;  Division of Hematology/Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, United States of America aff005;  Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina, United States of America aff006;  Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina, United States of America aff007
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article



Limited information exist on tobacco and e-cigarette use patterns in cancer survivors. The purpose of this study is to report on use patterns in cancer survivors compared with non-cancer participants from the Population Assessment of Tobacco and Health (PATH) Study.


Sociodemographic data and tobacco product use were analyzed for 32,244 adult participants from the PATH Study in 2013–2014 by cancer status and age. Logistic regression examined the patterns of and factors associated with tobacco use by cancer status.


Overall, cancer survivors represented 7.1% (n = 1,527) of participants, were older, and had a higher proportion of females and non-Hispanic whites than non-cancer participants. In cancer survivors, current and former cigarette smoking was reported in 12.7% and 32.9% respectively, compared with 18.5% and 19.0% in non-cancer adults. Current e-cigarette use was reported by 3.8% of survivors compared with 5.7% of non-cancer participants. Dual tobacco use was reported by 25.0% and poly use by 6.9% of cancer survivors who currently smoked. All other forms of current tobacco use were individually reported by <5% of survivors. Young adult cancer survivors (aged 18–44) reported the highest rates of current cigarette smoking (27.9%) and current e-cigarette use (11.8%). The effects of age, sex, race/ethnicity, education, and income on tobacco use status were comparable for cancer survivors and non-cancer participants. Cancer survivors who were younger, male, of lower educational attainment, and those diagnosed with a tobacco-related cancer were more likely to report current tobacco use.


Among cancer survivors, cigarette smoking remains the predominant form of tobacco use, although other tobacco/nicotine use and dual/poly use are common. The PATH Study provides detailed tobacco product use patterns in survivors, including their adoption of emerging alternative tobacco products.

Klíčová slova:

Age groups – Cancer detection and diagnosis – Cancer treatment – Educational attainment – Electronic cigarettes – Graduates – Schools – Smoking habits


1. US Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. In: Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2014.

2. Warren GW, Cartmell KB, Garrett-Mayer E, Salloum RG, Cummings KM. Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer. JAMA Netw Open. 2019;2: e191703. doi: 10.1001/jamanetworkopen.2019.1703 30951159

3. Bellizzi KM, Rowland JH, Jeffery DD, McNeel T. Health behaviors of cancer survivors: Examining opportunities for cancer control intervention. J Clin Oncol. 2005;23: 8884–8893. doi: 10.1200/JCO.2005.02.2343 16314649

4. Mayer DK, Carlson J. Smoking patterns in cancer survivors. Nicotine Tob Res. 2011;13: 34–40. doi: 10.1093/ntr/ntq199 21097514

5. Kasza KA, Ambrose BK, Conway KP, Borek N, Taylor K, Goniewicz ML, et al. Tobacco-Product Use by Adults and Youths in the United States in 2013 and 2014. N Engl J Med. 2017;376: 342–353. doi: 10.1056/NEJMsa1607538 28121512

6. Salloum RG, Getz KR, Tan ASL, Carter-Harris L, Young-Wolff KC, George TJ, et al. Use of Electronic Cigarettes Among Cancer Survivors in the U.S. Am J Prev Med. 2016;51: 762–766. doi: 10.1016/j.amepre.2016.04.015

7. Sanford NN, Sher DJ, Xu X, Aizer AA, Mahal BA. Trends in Smoking and e-Cigarette Use among US Patients with Cancer, 2014–2017. JAMA Oncology. 2019. doi: 10.1001/jamaoncol.2018.6858 30763430

8. Kruse GR, Kalkhoran S, Rigotti NA. Use of Electronic Cigarettes Among U.S. Adults With Medical Comorbidities. 2017. doi: 10.1016/j.amepre.2016.12.004 28108191

9. Fahey MC, Bursac Z, Ebbert JO, Klesges RC, Little MA. Prevalence and correlates of dual tobacco use in cancer survivors. 2019;4: 217–223. doi: 10.1007/s10552-019-1132-6 30671688

10. Congress 111th United States. Family Smoking Prevention and Tobacco Control Act. United States of America; 2009.

11. Hyland A, Ambrose BK, Conway KP, Borek N, Lambert E, Carusi C, et al. Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. Tob Control. 2017;26: 371–378. doi: 10.1136/tobaccocontrol-2016-052934 27507901

12. Symes YR, Ribisl KM, Boynton MH, Westmaas JL, Mayer DK, Golden SD. Dual cigarette and e-cigarette use in cancer survivors: an analysis using Population Assessment of Tobacco Health (PATH) data. Journal of Cancer Survivorship. 2019. doi: 10.1007/s11764-019-0735-y 30675695

13. Hyland A, Ambrose BK, Conway KP, Borek N, Lambert E, Carusi C, et al. Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. Tob Control. 2016; tobaccocontrol-2016-052934. doi: 10.1136/tobaccocontrol-2016-052934 27507901

14. McCarthy PJ. Pseudoreplication Further Evaluation and Application of the Balanced Half-Sample Technique. Vital Heal Stat. 1969;2: 1–24. Available:

15. Judkins DR. Fay’s method for variance estimation. Journal of Official Statistics. 1990. pp. 223–239. Available:

16. King B, Dube SR, Tynan M. Current tobacco use among adults in the United States: Findings from the National Adult Tobacco Survey. Am J Public Health. 2012;102: 93–100. doi: 10.2105/AJPH.2012.301002 22994278

17. National Cancer Institute. Cancer Survivors and Smoking. In: Cancer Trends Progress Report [Internet]. 2015 [cited 29 Oct 2018].

18. The National Academies of Science-Engineering-Medicine. Public Health Consequences of E-Cigarettes: Highlights. Washington, DC; 2018.

19. Cummings KM, Dresler CM, Field JK, Fox J, Gritz ER, Hanna NH, et al. E-cigarettes and cancer patients. Journal of Thoracic Oncology. 2014. pp. 438–441. doi: 10.1097/JTO.0000000000000129 24736063

20. Morgan G, Schnoll RA, Alfano CM, Evans SE, Goldstein A, Ostroff J, et al. National Cancer Institute Conference on Treating Tobacco Dependence at Cancer Centers. J Oncol Pract. 2011;7: 178–182. doi: 10.1200/JOP.2010.000175 21886500

21. Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. The Lancet Oncology. 2014. pp. e568–e580. doi: 10.1016/S1470-2045(14)70266-9 25439699

22. Gritz ER, Fingeret MC, Vidrine DJ, Lazev AB, Mehta N V., Reece GP. Successes and failures of the teachable moment. Cancer. 2005. pp. 17–27.

23. Hanna N, Mulshine J, Wollins DS, Tyne C, Dresler C. Tobacco Cessation and Control a Decade Later: American Society of Clinical Oncology Policy Statement Update. J Clin Oncol. 2013;31: 3147–3157. doi: 10.1200/JCO.2013.48.8932 23897958

24. Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, et al. Smoking cessation, version 1.2016 clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw. 2016;14: 1430–1468. 27799513

25. Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, et al. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. J Thorac Oncol. 2013;8: 543–548. doi: 10.1097/JTO.0b013e318288dc96 23529191

26. Warren GW, Dibaj S, Hutson A, Cummings KM, Dresler C, Marshall JR. Identifying targeted strategies to improve smoking cessation support for cancer patients. J Thorac Oncol. 2015;10: 1532–1537. doi: 10.1097/JTO.0000000000000659 26317914

27. Westmaas JL, Newton CC, Stevens VL, Flanders WD, Gapstur SM, Jacobs EJ. Does a recent cancer diagnosis predict smoking cessation? An analysis from a large prospective US cohort. J Clin Oncol. 2015;33: 1647–1652. doi: 10.1200/JCO.2014.58.3088 25897151

28. Croyle RT, Morgan GD, Fiore MC. Addressing a Core Gap in Cancer Care—The NCI Moonshot Program to Help Oncology Patients Stop Smoking. N Engl J Med. 2019;380: 512–515. doi: 10.1056/NEJMp1813913 30601710

29. Hewitt M, Breen N, Devesa S. Cancer prevalence and survivorship issues: Analyses of the 1992 national health interview survey. J Natl Cancer Inst. 1999;91: 1480–1486. doi: 10.1093/jnci/91.17.1480 10469749

30. Morales NA, Romano MA, Michael Cummings K, Marshall JR, Hyland AJ, Hutson A, et al. Accuracy of self-reported tobacco use in newly diagnosed cancer patients. Cancer Causes Control. 2013;24: 1223–1230. doi: 10.1007/s10552-013-0202-4 23553611

31. Warren GW, Arnold SM, Valentino JP, Gal TJ, Hyland AJ, Singh AK, et al. Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiother Oncol. 2012;103: 45–48. doi: 10.1016/j.radonc.2011.11.003 22119370

32. Khuri FR, Kim ES, Lee JackJ, Winn RJ, Benner SE, Lippman SM, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2001;10: 823–829. 11489748

Článek vyšel v časopise


2019 Číslo 12
Nejčtenější tento týden